|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net income (loss) | |||||
| Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | |||||
| Share-based compensation expense | |||||
| Depreciation and amortization | |||||
| Change in fair value of contingent obligations, net | |||||
| Amortization of deferred financing costs | |||||
| Deferred income taxes | |||||
| Gain on sale of travel health business | |||||
| Noncash gain on sale of business | |||||
| Change in fair value of warrant liability | |||||
| Goodwill impairment | |||||
| Impairment of long-lived assets | |||||
| Write off of contract asset and liability | |||||
| Loss on disposal of assets | |||||
| Other | |||||
| Changes in operating assets and liabilities: | |||||
| Accounts receivable | |||||
| Inventories | |||||
| Prepaid expenses and other assets | |||||
| Accounts payable | |||||
| Accrued expenses and other liabilities | |||||
| Long-term incentive plan accrual | |||||
| Accrued compensation | |||||
| Income taxes receivable and payable, net | |||||
| Contract liabilities | |||||
| Net cash provided by (used in) operating activities | |||||
| Investing Activities | |||||
| Purchases of property, plant and equipment | |||||
| Proceeds from sale of property, plant and equipment | |||||
| Royalty settlement payment | |||||
| Milestone payments from prior asset divestiture | |||||
| Asset acquisitions | |||||
| Purchase of convertible note receivable | |||||
| Proceeds from sale of business | |||||
| Net cash provided by investing activities | |||||
| Financing Activities | |||||
| Proceeds from the issuance of debt, net of lender fees | |||||
| Proceeds allocated to warrants issued in conjunction with debt | |||||
| Proceeds allocated to common stock issued in conjunction with debt | |||||
| Principal payments on term loan facility | |||||
| Proceeds from revolving credit facility | |||||
| Principal payments on revolving credit facility | |||||
| Debt issuance costs | |||||
| Proceeds from issuance of common stock upon exercise of stock options | |||||
| Repurchase of debt | |||||
| Prepayment premium on debt principal payment | |||||
| Purchases of treasury stock | |||||
| Principal payments on convertible senior notes | |||||
| Proceeds from share-based compensation activity | |||||
| Proceeds from at-the-market sale of stock, net of commissions and expenses | |||||
| Contingent consideration payments | |||||
| Taxes paid for share-based compensation activity | |||||
| Net cash used in financing activities: | |||||
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | |||||
| Net change in cash, cash equivalents and restricted cash | |||||
| Cash, cash equivalents and restricted cash, beginning of period | |||||
| Cash, cash equivalents and restricted cash, end of period | |||||
| Supplemental cash flow disclosures: | |||||
| Cash paid for interest | |||||
| Cash paid for income taxes, net of refunds | |||||
| Non-cash investing and financing activities: | |||||
| Purchases of property, plant and equipment unpaid at period end | |||||
| Purchases of treasury stock unpaid at period end | |||||
| Gain (loss) on extinguishments of debt | |||||
| Issuance of common stock in conjunction with debt | |||||
| Excise tax liability accrued for common stock repurchases | |||||
| Reconciliation of cash and cash equivalents and restricted cash: | |||||
| Cash and cash equivalents | |||||
| Restricted cash |
Loading...
